This July, Fexinidazole received approval by the FDA as an oral drug for the treatment of African trypanosomiasis (otherwise sleeping sickness). Though it was known since the 1970s, its development was initiated by the DNDi in the 2000s.

Fexinidazole shows antiparasitic activity and contains nitroimidazole in its backbone.

We have made a set of Building Blocks, which contain such parts – the perfect start for your research!